Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine Regimens in Older Patients with Untreated AML
NCT02096055Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2014
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of guadecitabine in acute myeloid leukemia (AML) (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Complete Remission Rate, Remission Duration and 3 more. Started Apr 2014; status: completed.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02096055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096055.